Prognostic impact of prior androgen receptor axis-targeting agents in cabazitaxel chemotherapy after docetaxel

Masaki Shiota; Motonobu Nakamura; Akira Yokomizo; Toshihisa Tomoda; Naotaka Sakamoto; Narihito Seki; Shuji Hasegawa; Takakazu Yunoki; Masahiko Harano; Kentaro Kuroiwa; E. T.O. Masatoshi

doi:10.21873/anticanres.13957

Prognostic impact of prior androgen receptor axis-targeting agents in cabazitaxel chemotherapy after docetaxel

Masaki Shiota, Motonobu Nakamura, Akira Yokomizo, Toshihisa Tomoda, Naotaka Sakamoto, Narihito Seki, Shuji Hasegawa, Takakazu Yunoki, Masahiko Harano, Kentaro Kuroiwa, E. T.O. Masatoshi

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Background/Aim: The novel taxane cabazitaxel has been shown to exert excellent anticancer effects after androgen receptor axis-targeting (ARAT) agents in clinical data, but not in in vitro data. We investigated the clinical outcome of cabazitaxel chemotherapy after docetaxel according to use of ARAT agents. Patients and Methods: Prostate specific antigen (PSA) response, progression-free survival, and overall survival were compared between cases with and without prior use of ARAT agents in 74 Japanese patients with metastatic castration-resistant prostate cancer treated with cabazitaxel chemotherapy. Results: Background characteristics were comparable between patients with and without prior use of ARAT agents. PSA response, progression-free survival, and overall survival in cabazitaxel chemotherapy were comparable between patients with and without prior use of ARAT agents. Conclusion: No detrimental effects of prior ARAT agents on clinical outcome were observed for cabazitaxel chemotherapy in the postdocetaxel setting, suggesting that cabazitaxel can be expected to remain active even after ARAT agent therapy.

Original language	English
Pages (from-to)	335-339
Number of pages	5
Journal	Anticancer research
Volume	40
Issue number	1
DOIs	https://doi.org/10.21873/anticanres.13957
Publication status	Published - 2020

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.13957

Cite this

@article{88f8ef9b96bc4b04a8eb36049509057f,

title = "Prognostic impact of prior androgen receptor axis-targeting agents in cabazitaxel chemotherapy after docetaxel",

abstract = "Background/Aim: The novel taxane cabazitaxel has been shown to exert excellent anticancer effects after androgen receptor axis-targeting (ARAT) agents in clinical data, but not in in vitro data. We investigated the clinical outcome of cabazitaxel chemotherapy after docetaxel according to use of ARAT agents. Patients and Methods: Prostate specific antigen (PSA) response, progression-free survival, and overall survival were compared between cases with and without prior use of ARAT agents in 74 Japanese patients with metastatic castration-resistant prostate cancer treated with cabazitaxel chemotherapy. Results: Background characteristics were comparable between patients with and without prior use of ARAT agents. PSA response, progression-free survival, and overall survival in cabazitaxel chemotherapy were comparable between patients with and without prior use of ARAT agents. Conclusion: No detrimental effects of prior ARAT agents on clinical outcome were observed for cabazitaxel chemotherapy in the postdocetaxel setting, suggesting that cabazitaxel can be expected to remain active even after ARAT agent therapy.",

author = "Masaki Shiota and Motonobu Nakamura and Akira Yokomizo and Toshihisa Tomoda and Naotaka Sakamoto and Narihito Seki and Shuji Hasegawa and Takakazu Yunoki and Masahiko Harano and Kentaro Kuroiwa and Masatoshi, {E. T.O.}",

note = "Funding Information: This work was supported by a JSPS KAKENHI grant (17K11145). The Authors would like to acknowledge the contributions of the following collaborators: Akito Yamaguchi at Harasanshin Hospital (Fukuoka), Takashi Dejima at Kyushu Central Hospital (Fukuoka), Satoshi Otsubo at Kitakyushu Municipal Medical Center (Kitakyushu), Akio Tsutsui at JCHO Kyushu Hospital (Kitakyushu), and Yoshifumi Hori at Miyazaki Prefectural Miyazaki Hospital (Miyazaki). The Authors also thank Alison Sherwin, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. Publisher Copyright: {\textcopyright} 2020 International Institute of Anticancer Research. All rights reserved.",

year = "2020",

doi = "10.21873/anticanres.13957",

language = "English",

volume = "40",

pages = "335--339",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "1",

}

TY - JOUR

T1 - Prognostic impact of prior androgen receptor axis-targeting agents in cabazitaxel chemotherapy after docetaxel

AU - Shiota, Masaki

AU - Nakamura, Motonobu

AU - Yokomizo, Akira

AU - Tomoda, Toshihisa

AU - Sakamoto, Naotaka

AU - Seki, Narihito

AU - Hasegawa, Shuji

AU - Yunoki, Takakazu

AU - Harano, Masahiko

AU - Kuroiwa, Kentaro

AU - Masatoshi, E. T.O.

N1 - Funding Information: This work was supported by a JSPS KAKENHI grant (17K11145). The Authors would like to acknowledge the contributions of the following collaborators: Akito Yamaguchi at Harasanshin Hospital (Fukuoka), Takashi Dejima at Kyushu Central Hospital (Fukuoka), Satoshi Otsubo at Kitakyushu Municipal Medical Center (Kitakyushu), Akio Tsutsui at JCHO Kyushu Hospital (Kitakyushu), and Yoshifumi Hori at Miyazaki Prefectural Miyazaki Hospital (Miyazaki). The Authors also thank Alison Sherwin, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript. Publisher Copyright: © 2020 International Institute of Anticancer Research. All rights reserved.

PY - 2020

Y1 - 2020

N2 - Background/Aim: The novel taxane cabazitaxel has been shown to exert excellent anticancer effects after androgen receptor axis-targeting (ARAT) agents in clinical data, but not in in vitro data. We investigated the clinical outcome of cabazitaxel chemotherapy after docetaxel according to use of ARAT agents. Patients and Methods: Prostate specific antigen (PSA) response, progression-free survival, and overall survival were compared between cases with and without prior use of ARAT agents in 74 Japanese patients with metastatic castration-resistant prostate cancer treated with cabazitaxel chemotherapy. Results: Background characteristics were comparable between patients with and without prior use of ARAT agents. PSA response, progression-free survival, and overall survival in cabazitaxel chemotherapy were comparable between patients with and without prior use of ARAT agents. Conclusion: No detrimental effects of prior ARAT agents on clinical outcome were observed for cabazitaxel chemotherapy in the postdocetaxel setting, suggesting that cabazitaxel can be expected to remain active even after ARAT agent therapy.

AB - Background/Aim: The novel taxane cabazitaxel has been shown to exert excellent anticancer effects after androgen receptor axis-targeting (ARAT) agents in clinical data, but not in in vitro data. We investigated the clinical outcome of cabazitaxel chemotherapy after docetaxel according to use of ARAT agents. Patients and Methods: Prostate specific antigen (PSA) response, progression-free survival, and overall survival were compared between cases with and without prior use of ARAT agents in 74 Japanese patients with metastatic castration-resistant prostate cancer treated with cabazitaxel chemotherapy. Results: Background characteristics were comparable between patients with and without prior use of ARAT agents. PSA response, progression-free survival, and overall survival in cabazitaxel chemotherapy were comparable between patients with and without prior use of ARAT agents. Conclusion: No detrimental effects of prior ARAT agents on clinical outcome were observed for cabazitaxel chemotherapy in the postdocetaxel setting, suggesting that cabazitaxel can be expected to remain active even after ARAT agent therapy.

UR - http://www.scopus.com/inward/record.url?scp=85077446182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077446182&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13957

DO - 10.21873/anticanres.13957

M3 - Article

C2 - 31892584

AN - SCOPUS:85077446182

SN - 0250-7005

VL - 40

SP - 335

EP - 339

JO - Anticancer research

JF - Anticancer research

IS - 1

ER -

Prognostic impact of prior androgen receptor axis-targeting agents in cabazitaxel chemotherapy after docetaxel

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this